Bausch Health shares fall 1.61% premarket after Q2 adjusted net income drops.

Bausch Health Companies Inc. fell 1.61% in premarket trading. The company entered into an Agreement and Plan of Merger to acquire DURECT Corporation for $63 million, but the acquisition price of $1.75 per share is being investigated by Halper Sadeh LLC for potential violations of federal securities laws and breaches of fiduciary duties. Additionally, Bausch + Lomb's Q2 adjusted net income fell, although revenue rose and guidance was updated.